MedTrace Logo

A Study to Assess the Mass Balance and ADME of [14C]AZD5004 and the Absolute Bioavailability of AZD5004

NCT06857695 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2025-05-28

No results posted yet for this study

Summary

This study in healthy volunteers aims to answer these questions:

* Does the test medicine cause any important side effects?
* What are the blood levels of the test medicine and how quickly does the body get rid of it?
* How much of the test medicine taken by mouth gets into the bloodstream?
* How does the body break down and get rid of the test medicine?

This study will take place at one site in Nottingham, United Kingdom, and plans to enrol 8 healthy men aged 30-65 years, who will be involved in both parts of the study.

Conditions

  • Healthy Participants

Interventions

DRUG

AZD5004 film-coated tablet

oral, fasted

DRUG

[14C]AZD5004 Solution for Infusion

intravenous, fasted

DRUG

[14C]AZD5004 Oral Solution

oral, fasted

Sponsors & Collaborators

  • Quotient Sciences

    collaborator INDUSTRY

  • AstraZeneca

    lead INDUSTRY

Principal Investigators

  • Sharan Sidhu, MBChB, BAO, MRCS, MFPM · Quotient Sciences

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
30 Years
Max Age
65 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-03-06
Primary Completion
2025-05-05
Completion
2025-05-05

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06857695 on ClinicalTrials.gov